PT  - JOURNAL ARTICLE
AU  - Brian D. Southern
TI  - Patients with interstitial lung disease and pulmonary sarcoidosis are at high risk for severe illness related to COVID-19
AID  - 10.3949/ccjm.87a.ccc026
DP  - 2020 May 14
TA  - Cleveland Clinic Journal of Medicine
4099  - http://www.ccjm.org/content/early/2020/06/16/ccjm.87a.ccc026.short
4100  - http://www.ccjm.org/content/early/2020/06/16/ccjm.87a.ccc026.full
AB  - Analyses of COVID-19 patients with preexisting interstitial lung disease (ILD) or pulmonary sarcoidosis is lacking but registries are ongoing. Treatment of COVID-19 in patients with underlying ILD or sarcoidosis may include hospital admission, possible drug treatment, caution with steroids, and avoidance of mechanical ventilation in acute exacerbation of ILD. Patients with COVID-19 respiratory illness are at risk for developing ILD.